Nurr1 Receptor Modulators for Parkinson's Disease Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease primarily focus on alleviating symptoms through dopamine augmentation or receptor agonism, but they do not effectively slow or stop the progression of the disease, and they come with significant side effects, highlighting the need for new therapeutic approaches that address both symptom management and disease progression.
Innovation Solution
A pharmaceutical compound with a specific formula that modulates the activity of Nurr1, a protein crucial for dopaminergic neuron health, is administered to increase dopamine levels and improve motor function, potentially slowing disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If existing dopaminergic therapies (L-DOPA, MAO inhibitors, COMT inhibitors, dopamine agonists) are used to alleviate Parkinson's disease symptoms, then motor function is improved, but the disease progression is not slowed and significant side effects occur
Solution Approach 1:
The patent introduces Nurr1 as an intermediary nuclear receptor that mediates the protective effects against dopaminergic neuron death. By designing small molecule compounds that specifically activate Nurr1, the therapy indirectly protects neurons through this intermediary pathway rather than directly augmenting dopamine, thereby addressing both symptom relief and disease progression while reducing side effects associated with direct dopaminergic stimulation.
2Ease of operation
If high doses of dopaminergic drugs are administered to manage severe symptoms, then motor function is maintained, but side effects increase significantly
Solution Approach 1:
The patent changes the therapeutic parameter from direct dopaminergic stimulation to Nurr1 receptor activation. The small molecule compounds described activate Nurr1 with high specificity and potency, producing dopaminergic neuron protection and symptom relief through a different molecular pathway that avoids the side effects of traditional high-dose dopaminergic therapies.
3Ease of operation
If current therapeutic mechanisms (dopamine augmentation, enzyme inhibition, receptor agonism) are used, then symptom relief is achieved, but neuronal protection is insufficient
Solution Approach 1:
The patent segments the therapeutic approach into two distinct mechanisms: (1) symptom relief through dopaminergic pathway modulation via Nurr1 activation, and (2) neuronal protection through Nurr1-mediated transcriptional regulation of protective genes. This segmentation allows simultaneous achievement of both symptom management and neuroprotection that was not possible with unified traditional therapies.
Data Source
AI summary
Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.